Comparing Scienture (NASDAQ:SCNX) & Enanta Pharmaceuticals (NASDAQ:ENTA)

Scienture (NASDAQ:SCNX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Institutional and Insider Ownership

5.7% of Scienture shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 21.4% of Scienture shares are held by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Scienture and Enanta Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430,000.00	31.84	-$41.51 million	($2.76)	-0.12
Enanta Pharmaceuticals	$65.32 million	6.50	-$81.89 million	($3.20)	-4.57

Scienture has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Scienture has a beta of 3.15, suggesting that its share price is 215% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Scienture and Enanta Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1	0	1	0	2.00
Enanta Pharmaceuticals	1	0	7	0	2.75

Scienture presently has a consensus target price of $1.50, indicating a potential upside of 345.10%. Enanta Pharmaceuticals has a consensus target price of $20.29, indicating a potential upside of 38.66%. Given Scienture’s higher possible upside, analysts plainly believe Scienture is more favorable than Enanta Pharmaceuticals.

Profitability

This table compares Scienture and Enanta Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.25%	-41.55%
Enanta Pharmaceuticals	-106.80%	-78.58%	-23.18%

Summary

Scienture beats Enanta Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.